SecBot SecBot
144 ·Filed Nov 2, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed14d 8h ago SEC0001957799-26-000192
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The proposed sale is small and by a director, not the CEO/CFO, so it carries limited signal. Monitor for any larger insider sales or changes in insider filing patterns, but this filing alone does not warrant concern.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$313.52
T+0 close · Nov 2, 2026 · via day close
Latest settled
+0.20%
T+5 · $314.16 · next T+20 in 15d
Vs SPY
+0.79%
α at T+5
Latest observation
−0.74%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $313.52entry
  2. T+1 · 13d ago +0.83%α −0.82% · $316.13
  3. T+5 · 7d ago +0.20%α +0.79% · $314.16
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Jason Aryeh, a director of Ligand Pharmaceuticals, filed a Form 144 notice of intent to sell 700 shares of Class B common stock, with an approximate market value of $221,595. The shares were acquired between May and July 2019 via secondary market purchases. The sale is small relative to the company's $6.3B market cap and the insider's likely total holdings, making it a routine diversification move.

Key Facts

  • Jason Aryeh, a director, filed Form 144 to sell 700 shares of Class B common stock.
  • Estimated proceeds of $221,595 based on filing date price.
  • Shares were acquired between May 14, 2019 and July 30, 2019 via secondary market purchases.
  • The sale represents a tiny fraction of the company's $6.3B market cap.
  • The filing is an advance notice of intent to sell, not a completed transaction.

Financial Impact

Sale of 700 shares valued at approximately $221,595, negligible relative to $6.3B market cap.

dilution

Risk Factors

  • Form 144 is only an intent to sell; the sale may not occur.
  • No context on the insider's total holdings, so proportionality is estimated.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001957799-26-000192
Document: 0001957799-26-000192-index.html0001957799-26-000192
Document: 0001957799-26-000192.txt0001957799-26-000192

US Market Status

Market Closed · Opens in 8h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026